Macrophages have emerged as one of the most versatile and actionable cell populations in modern immunotherapy. Positioned at the intersection of innate and adaptive immunity, these cells can detect danger signals, reshape the tumor or inflammatory microenvironment, regulate antigen presentation, coordinate tissue remodeling, and influence the recruitment and function of T cells, NK cells, dendritic cells, fibroblasts, and other immune subsets. Their remarkable plasticity also makes them uniquely attractive as both therapeutic targets and therapeutic carriers. As a result, macrophage-based immunotherapy is rapidly evolving from a conceptual strategy into a practical development direction across oncology, autoimmune disorders, infectious diseases, fibrosis, and regenerative medicine.

At Creative Biolabs, we provide a comprehensive immunotherapy using macrophages service to help clients explore, validate, and advance macrophage-centered therapeutic programs from discovery through preclinical translation.

Why Macrophages for Immunotherapy?

Macrophages are increasingly recognized as central orchestrators of disease progression and therapeutic response. In tumors, macrophages often become polarized into immunosuppressive, pro-angiogenic, matrix-remodeling, and metastasis-supporting populations that limit the efficacy of checkpoint blockade, CAR-T therapies, and other immune interventions. In inflammatory and autoimmune diseases, macrophages can amplify cytokine cascades, sustain chronic tissue injury, promote osteoclastogenesis or fibrosis, and block the return to immune homeostasis. At the same time, macrophages also possess powerful anti-tumor and tissue-repair functions when properly activated or reprogrammed. This duality is precisely what makes them so compelling as immunotherapy targets.

Fig. 1 Tumor cells can be regulated by macrophages.^1,2

Several therapeutic strategies can be built around macrophage biology.

• One approach aims to deplete pathogenic macrophage subsets selectively, reducing their contribution to disease-promoting inflammation or immune suppression.
• A second strategy seeks to block macrophage recruitment, survival, or signaling pathways, thereby interrupting the generation and maintenance of harmful macrophage populations.
• A third and increasingly exciting strategy involves re-educating macrophages from a disease-promoting state toward an immune-activating or pro-resolving phenotype.
• Still another direction involves engineering macrophages themselves as cellular therapeutic tools—using them as living delivery systems, phagocytic effectors, or regulators of local immunity.

Successful macrophage immunotherapy development requires more than a simple polarization assay. It demands systems that capture macrophage heterogeneity, disease-relevant activation cues, cell-cell interactions, spatial context, and meaningful functional readouts. Creative Biolabs addresses this challenge through a robust service platform that combines cell sourcing, macrophage differentiation, phenotype induction, co-culture modeling, multi-parametric analytics, and engineering technologies.

Our Macrophage Immunotherapy Service Portfolio

Understanding and advancing macrophage-based immunotherapy requires a multidimensional experimental strategy. We therefore offer a broad, modular, and fully customizable service portfolio to support clients across target discovery, candidate profiling, mechanism-of-action studies, proof-of-concept validation, and preclinical optimization.

Macrophage Isolation, Differentiation, and Polarization

We establish macrophage systems tailored to your indication and mechanism of action. Depending on project needs, we work with primary human monocytes, PBMC-derived macrophages, tissue-derived macrophages, iPSC-derived macrophages, murine macrophages, and validated myeloid cell lines. Our team can generate macrophage populations under standard or disease-mimetic conditions, using defined cytokines, growth factors, metabolic cues, hypoxia, stromal signals, exosomes, or tumor-conditioned media to reflect real-world biological complexity.

We support classical and non-classical macrophage state generation, including M1-like inflammatory phenotypes, M2-like suppressive or repair-associated phenotypes, tumor-associated macrophage-like states, fibrosis-associated macrophage states, and custom polarization protocols aligned with your indication. Beyond surface marker confirmation, we profile cytokine outputs, metabolic signatures, phagocytic activity, antigen-presentation features, transcriptional response programs, and pathway activation status.

Macrophage Phenotyping and Functional Characterization

Our characterization package includes high-parameter flow cytometry, immunofluorescence, immunohistochemistry, cytokine multiplexing, ELISA, qPCR, bulk RNA sequencing, selected single-cell workflows, phagocytosis assays, efferocytosis assays, migration assays, invasion support assays, and metabolic analysis. We can measure canonical and customized biomarker panels including markers linked to inflammatory activation, immunoregulation, antigen presentation, chemotaxis, scavenging, matrix remodeling, and checkpoint-related suppression.

Macrophage–Tumor and Macrophage–Immune Cell Interaction Assays

Because macrophages rarely act in isolation, we offer a comprehensive set of interaction assays to model their influence within complex cellular ecosystems. In oncology, these systems may include macrophage co-culture with tumor cells, cancer-associated fibroblasts, endothelial cells, T cells, NK cells, dendritic cells, or myeloid suppressor populations.

For inflammatory disease applications, we design co-culture and conditioned-media systems that recapitulate macrophage interactions with fibroblasts, synoviocytes, epithelial cells, osteoclast precursors, mesenchymal stromal cells, and adaptive immune populations.

Macrophage Reprogramming and Immunomodulation Studies

Our reprogramming workflows can investigate pathway-specific or systems-level mechanisms. We routinely assess candidate impact on cytokine signaling, NF-kB and JAK/STAT pathways, metabolic switching, hypoxia adaptation, epigenetic state, phagocytosis checkpoints, and receptor-mediated activation. We can also compare reprogramming durability after withdrawal of the stimulus, under repeated suppressive conditioning, or in the presence of disease-relevant stromal cues.

Engineered Macrophage Development

Our platform supports exploratory and preclinical development of macrophage engineering strategies, including receptor engineering, cargo loading, nanoparticle coupling, exosome-mediated programming, membrane-based delivery systems, and gene-expression modulation workflows.

Therapeutic Strategies We Support

Macrophage immunotherapy is not a single modality; it is a strategy space. Creative Biolabs supports projects across several major development directions.

Typical Workflow

A successful macrophage immunotherapy program often benefits from a staged workflow.

• We commonly begin with project consultation and mechanism alignment to clarify the therapeutic concept, disease context, target biology, and desired decision points.
• We then establish the most relevant macrophage source and conditioning method, followed by baseline phenotyping and functional assay setup.
• Candidate agents are screened through a tiered cascade that may include viability, phenotype shift, cytokine modulation, phagocytosis, co-culture performance, and signaling analysis.
• The most promising candidates can then move into expanded mechanism studies, delivery evaluation, or in vivo validation.

Applications

Our immunotherapy using macrophages service can support programs in a wide range of therapeutic areas, including:

• Solid tumor immunotherapy and TAM reprogramming
• Hematologic malignancies with myeloid-driven suppression
• Autoimmune and inflammatory diseases
• Fibrosis and chronic tissue remodeling disorders
• Infection-associated immune dysregulation
• Regenerative medicine and tissue repair research
• Targeted nanomedicine and cell-mediated delivery development
• Next-generation engineered macrophage therapy programs

Related Products

To support macrophage programs, Creative Biolabs also offers a wide range of related products and enabling materials. These products can be incorporated into integrated service packages to streamline your development workflow.

Scientific Resources

Q & A

Q: What kinds of projects are suitable for this service?

A: This service is suitable for a broad range of discovery and preclinical programs in which macrophages are involved as disease-driving cells, therapeutic targets, delivery vehicles, or engineered effectors. Typical projects include tumor-associated macrophage modulation, inflammatory macrophage characterization, macrophage reprogramming studies, development of macrophage-targeted drug delivery systems, mechanistic evaluation of immunomodulatory candidates, and engineered macrophage cell therapy research.

Q: Can macrophages be used directly as therapeutic cells?

A: Yes. Macrophages can be developed as direct therapeutic agents in cell-based immunotherapy programs. Compared with some other immune cell types, macrophages offer distinct advantages such as strong tissue infiltration, natural phagocytic activity, responsiveness to environmental cues, and the ability to function within solid tissues and suppressive microenvironments. They can also be engineered to carry therapeutic payloads, express defined receptors, or enhance anti-disease functions. Because this area is still rapidly evolving, development requires careful optimization of cell source, phenotype stability, delivery method, and functional performance, which is exactly where dedicated macrophage development services can be highly valuable.

Q: Do you work with both primary macrophages and cell lines?

A: Yes. We support projects using multiple macrophage sources depending on the intended application. These may include primary human monocyte-derived macrophages, PBMC-derived macrophages, tissue-derived macrophages when appropriate, iPSC-derived macrophages, murine macrophages, and selected myeloid cell lines. Primary cells are often preferred when translational relevance is critical, while cell lines may be useful for feasibility studies, screening workflows, or early platform development. We can recommend or implement the most suitable system based on your scientific objectives, throughput needs, and budget considerations.

Q: Can you model tumor-associated macrophages (TAMs)?

A: Yes. We provide TAM-like model development using disease-relevant stimuli such as tumor-conditioned media, hypoxia, stromal signaling factors, metabolic stress conditions, and co-culture systems involving cancer cells and supporting microenvironmental components.

Q: What types of functional assays do you provide?

A: We offer a broad set of macrophage-focused functional assays. These include phagocytosis of labeled particles or target cells, efferocytosis of apoptotic cells, migration and chemotaxis studies, cytokine secretion analysis, antigen-presentation-related evaluation, tumor cell co-culture assays, immune-cell interaction assays, and so on.

If you are seeking a reliable partner to accelerate your macrophage immunotherapy program, Creative Biolabs is ready to support your project with scientific depth and practical execution.

References

1. Zhou, Li, et al. "New insights into the role of macrophages in cancer immunotherapy." Frontiers in immunology 15 (2024): 1381225. https://doi.org/10.3389/fimmu.2024.1381225
2. Distributed under Open Access license CC BY 4.0, without modification.